CN105920602B - Application of NF-κB p65/HMGCS2 regulatory pathway in the preparation of drugs for regulating ketone body synthesis - Google Patents
Application of NF-κB p65/HMGCS2 regulatory pathway in the preparation of drugs for regulating ketone body synthesis Download PDFInfo
- Publication number
- CN105920602B CN105920602B CN201610495233.2A CN201610495233A CN105920602B CN 105920602 B CN105920602 B CN 105920602B CN 201610495233 A CN201610495233 A CN 201610495233A CN 105920602 B CN105920602 B CN 105920602B
- Authority
- CN
- China
- Prior art keywords
- hmgcs2
- kappa
- promoter
- synthesis
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101000839020 Homo sapiens Hydroxymethylglutaryl-CoA synthase, mitochondrial Proteins 0.000 title claims abstract description 76
- 102100028889 Hydroxymethylglutaryl-CoA synthase, mitochondrial Human genes 0.000 title claims abstract description 73
- 102000005747 Transcription Factor RelA Human genes 0.000 title claims abstract description 57
- 108010031154 Transcription Factor RelA Proteins 0.000 title claims abstract description 57
- 150000002576 ketones Chemical class 0.000 title claims abstract description 42
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 28
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 25
- 229940079593 drug Drugs 0.000 title abstract description 23
- 230000001105 regulatory effect Effects 0.000 title abstract description 19
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 230000037361 pathway Effects 0.000 title abstract description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 10
- 230000002103 transcriptional effect Effects 0.000 claims abstract description 8
- 108090001005 Interleukin-6 Proteins 0.000 claims description 44
- 230000004770 neurodegeneration Effects 0.000 claims description 9
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 4
- 210000005229 liver cell Anatomy 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 abstract description 14
- 102000004190 Enzymes Human genes 0.000 abstract description 7
- 230000004060 metabolic process Effects 0.000 abstract description 6
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 5
- 239000003596 drug target Substances 0.000 abstract description 3
- 230000037149 energy metabolism Effects 0.000 abstract description 2
- 210000002569 neuron Anatomy 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 43
- 102000004889 Interleukin-6 Human genes 0.000 description 41
- 230000000694 effects Effects 0.000 description 32
- 239000002609 medium Substances 0.000 description 17
- 238000011144 upstream manufacturing Methods 0.000 description 17
- 102100035100 Transcription factor p65 Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000001514 detection method Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000001276 controlling effect Effects 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 235000013305 food Nutrition 0.000 description 6
- 108020004459 Small interfering RNA Proteins 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108010000775 Hydroxymethylglutaryl-CoA synthase Proteins 0.000 description 4
- 230000002361 ketogenic effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102100028888 Hydroxymethylglutaryl-CoA synthase, cytoplasmic Human genes 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 230000001195 anabolic effect Effects 0.000 description 3
- 210000003855 cell nucleus Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108091035710 E-box Proteins 0.000 description 2
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 description 2
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000009094 Hepatocyte Nuclear Factor 3-beta Human genes 0.000 description 2
- 108010087745 Hepatocyte Nuclear Factor 3-beta Proteins 0.000 description 2
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 2
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 235000020887 ketogenic diet Nutrition 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 230000006974 Aβ toxicity Effects 0.000 description 1
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 1
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 1
- 102100035421 Forkhead box protein O3 Human genes 0.000 description 1
- ZPLQIPFOCGIIHV-UHFFFAOYSA-N Gimeracil Chemical compound OC1=CC(=O)C(Cl)=CN1 ZPLQIPFOCGIIHV-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000877727 Homo sapiens Forkhead box protein O1 Proteins 0.000 description 1
- 101000877681 Homo sapiens Forkhead box protein O3 Proteins 0.000 description 1
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 101100017526 Homo sapiens HMGCS2 gene Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100030710 NAD-dependent protein deacetylase sirtuin-3, mitochondrial Human genes 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 108010028924 PPAR alpha Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 239000012721 SDS lysis buffer Substances 0.000 description 1
- 108091005770 SIRT3 Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000006571 energy metabolism pathway Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 229950009822 gimeracil Drugs 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 102000047486 human GAPDH Human genes 0.000 description 1
- 102000044454 human HMGCS2 Human genes 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 230000007334 memory performance Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000007076 release of cytoplasmic sequestered NF-kappaB Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000035322 succinylation Effects 0.000 description 1
- 238000010613 succinylation reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了NF‑κB p65/HMGCS2调控途径作为药物靶点在制备调控酮体合成的药物、保健品中的应用；NF‑κB p65通过HMGCS2启动子结合，从转录水平调控该酶的表达，HMGCS2影响酮体的合成水平；可以激活NF‑κB p65，从转录水平调控HMGCS2的表达，进而对酮体代谢进行调控，间接加强酮体合成，改善神经细胞等的能量代谢，最终起到防治神经退行性疾病的作用。The invention discloses the application of NF-κB p65/HMGCS2 regulation pathway as a drug target in the preparation of medicines and health products for regulating ketone body synthesis; NF-κB p65 is combined with HMGCS2 promoter to regulate the expression of the enzyme from the transcriptional level, HMGCS2 affects the synthesis level of ketone bodies; it can activate NF-κB p65, regulate the expression of HMGCS2 from the transcriptional level, and then regulate the metabolism of ketone bodies, indirectly strengthen the synthesis of ketone bodies, improve the energy metabolism of nerve cells, etc. The role of degenerative diseases.
Description
Technical Field
The invention belongs to the technical field of medicines for regulating and controlling ketone body synthesis, and relates to application of a NF-kappa B p65/HMGCS2 regulation and control approach in preparation of medicines for regulating and controlling ketone body synthesis.
Background
Ketone bodies are the collective term for acetoacetate, β -hydroxybutyrate (β -OHB) and acetone in mammals. Ketogenesis, the synthesis of ketone bodies, is a branch of mammalian metabolism. As levels of glucose metabolism decrease, levels of ketone bodies produced by the liver increase. The synthesis of ketone bodies occurs mainly in the liver, and moreover, astrocytes in the brain can also produce small amounts of ketone bodies. In the case of glucose insufficiency, ketone bodies are used as energy substrates for extrahepatic tissues.
In recent years, studies have found that ketone bodies appear early in AD as a surrogate for glucose energy supply and decline as the disease progresses. The research shows that the ketogenic diet has protective effect on neurodegenerative diseases such as Parkinson and AD. Medium chain triglycerides improve memory performance in AD patients, and memory improvement is positively correlated with beta OHB plasma levels produced by medium chain triglyceride oxidation. Further studies have shown that direct use of β OHB at concentrations consistent with ketogenic diets also has neuroprotective effects. bHB was found to protect hippocampal neurons against A β toxicity using a D-beta-hydroybutyrate (bHB) effect A β -induced AD cell model.
Through the regulation and control of some key enzymes in the ketonic process, the level of ketone bodies can be controlled, and further, the energy metabolic pathway in vivo is influenced. Wherein the process of controlling HMG-CoA formation by hydroxymethyl glutaryl-CoA synthetase (HMGCS 2) is the rate-limiting step in ketone body formation. Studies have shown that HMGCS2 is co-regulated at both the transcriptional and translational levels. At the transcriptional level, HMGCS2 is regulated by at least three pathways. One pathway involves the forkhead transcription factor FOXA2 (Forkhead box A2). FKHRL1 in the FOX family of transcription factors FKHR (forkhead in rhabdosaroma) is also involved in the regulation of the HMGCS2 transcriptional pathway. In addition, HMGCS2 transcriptional level regulation is associated with mTORC1 (mammlian target of rapamycin complex 1), PPAR α (Peroxisome promoter activated receptor α) and FGF21(Fibroblast growth factor 21). These transcription factors bind to the HMGCS2 promoter sequence and regulate the expression of the gene at the transcriptional level. At the translational level, the activity of HMGCS2 is also regulated by acetylation and succinylation. It was found that HMGCS2 contains some SIRT3 regulated acetylation sites. However, the modification and regulatory functions of these sites are not yet known.
The nuclear factor NF-kB is expressed in various cells and mainly relates to information transmission in the processes of body defense reaction, tissue injury and stress, cell differentiation, apoptosis and the like. NF-. kappa.B is in an inactive state in most cell cytoplasm, and is activated into the nucleus to affect transcription of genes when an information substance acts on a corresponding receptor. In addition, studies have demonstrated that inflammation plays an important role in fat metabolism and sugar metabolism. The production of inflammatory factors can inhibit liver fat synthesis and fatty liver formation.
Disclosure of Invention
The invention aims to provide the application of the NF-kappa B p65/HMGCS2 regulation and control approach in preparing a medicine for regulating and controlling ketone body synthesis, can be used as a molecular target for preparing ketogenic medicines and foods, and particularly can be used for preparing medicines and foods for preventing and treating neurodegenerative diseases.
The invention is realized by the following technical scheme:
the NF-kappa B p65/HMGCS2 regulation and control approach is used as a medicine target to prepare medicines and health care products for regulating and controlling ketone body synthesis.
The NF-kappa B p65/HMGCS2 regulation and control way is applied to the preparation of ketogenic drugs and health products as a drug target.
The NF-kappa B p65/HMGCS2 regulation and control approach is used as a medicine target to prepare medicines and health care products for preventing and treating neurodegenerative diseases.
The medicine and the health care product influence the combination of NF-kappa B p65 and a promoter of ketone body synthetase HMGCS2, regulate the expression of HMGCS2 from the transcription level and influence the synthesis level of ketone bodies.
The drug is a drug for activating NF-kappa B p65, enhances the expression of HMGCS2 from the transcription level and indirectly enhances the synthesis of ketone bodies.
The drug is an inflammatory factor, an expression vector or a compound drug for enhancing the expression of NF-kappa B p 65.
The drug is a drug which affects the binding site of NF-kappa B p65 and HMGCS2 promoter.
The drug enhances or inhibits the combination of NF-kappa B p65 and GGAAGACCT site on HMGCS2 promoter.
The application of a medicament for activating NF-kappa B p65 in preparing a medicament for regulating and controlling ketone body synthesis.
The application of a drug or a vector for regulating NF-kappa B p65 expression in preparing a drug for regulating the synthesis of ketone bodies.
Compared with the prior art, the invention has the following beneficial technical effects:
the NF-kappa B p65/HMGCS2 regulation and control approach provided by the invention is applied to the preparation of a medicine for regulating and controlling the synthesis of ketone bodies, NF-kappa B p65 is combined through an HMGCS2 promoter, the expression of the enzyme is regulated and controlled from the transcription level, and HMGCS2 influences the synthesis level of the ketone bodies; can activate NF-kappa B p65, regulate the expression of HMGCS2 from the transcription level, further regulate the metabolism of ketone bodies, indirectly enhance the synthesis of the ketone bodies, improve the energy metabolism of nerve cells and the like, and finally play a role in preventing and treating neurodegenerative diseases. The activation of NF-kappa B p65 can be realized by various ways, NF-kappa B p65 can be activated by molecules such as interleukin-6, and the expression of a ketobody beta OHB synthesis rate-limiting enzyme HMGCS2 can be promoted; provides a way to prevent and treat neurodegenerative diseases through relatively common medicines.
The NF-kappa B p65/HMGCS2 regulation and control approach of the invention depends on the combination of NF-kappa B p65 and HMGCS2 promoter, the experiment of the invention shows that the activity of HMGCS2 promoter can be increased by 40% by enhancing NF-kappa B p65 through IL-6, and the mRNA level of HMGCS2 is reduced by about 70% after NF-kappa BsiRNA p65 is knocked out of NF-kappa B p 65; the NF-kappa B p65 is enhanced through the combination effect of the E-box1 and the HMGCS2 promoter, thereby indirectly regulating and controlling the synthesis level of ketone bodies, so that the NF-kappa B p65/HMGCS2 regulation and control approach as a drug target can be applied to the preparation of ketogenic drugs and foods, in particular to the preparation of drugs and foods for preventing and treating neurodegenerative diseases.
Drawings
FIG. 1 is a graph of the effect of interleukin-6 on cell activity; the proliferation of cells was observed after treatment with different concentrations of IL-6.
FIG. 2-1 shows the result of detecting proteins of NF- κ B p65 activated by IL-6; FIG. 2-2 shows the fluorescence detection result of IL-6 activating NF- κ B p 65.
FIG. 3-1 is a graph showing the effect of IL-6 on the promotion of ketone body β OHB levels; FIG. 3-2 is a graph showing the effect of IL-6 on the level of mRNA for the ketone body anabolic enzyme HMGCS 2; FIGS. 3-3 are graphs showing the effect of IL-6 on protein levels of HMGCS 2; FIGS. 3-4 show the effect of IL-6 on the activity of the HMGCS2 promoter.
FIG. 4-1 shows the result of detecting HMGCS2mRNA level by NF- κ B p65 knock-out; FIG. 4-2 shows the results of detection of HMGCS2 protein level by NF- κ B p65 knock-out; FIGS. 4-3 show the results of the NF-. kappa. B p65 knock-out assay for HMGCS2 promoter activity.
FIG. 5-1 is a prediction of the potential NF-. kappa. B p65 binding site of the HMGCS2 promoter; FIG. 5-2 is a graph showing the detection of potential sites of the HMGCS2 promoter for NF- κ B p65 binding; FIGS. 5-3 are the assays of whether NF-. kappa. B p65 binds directly to the HMGCS2 promoter site.
Detailed Description
The present invention will now be described in further detail with reference to specific examples, which are intended to be illustrative, but not limiting, of the invention.
HepG2 is a liver cancer cell line and is a cell model commonly used for researching liver cells, IL-6 is a commonly used factor activated by NF-kappa B p65, transient transfection siRNA is a commonly used in-vitro knockout method, and in order to observe the influence of NF-kappa B p65 on the metabolism of liver cell ketone bodies and the action mechanism thereof, HepG2 is selected as a cell model, and the NF-kappa B p65siRNA method is adopted as a cell model for in-vitro knockout.
Effect of 1 IL-6 on cellular Activity
The confluent cells were passaged in 96-well plates, and 10 or 30ng/mL IL-6 was added after 24 hours, and cell viability was measured after incubation for 12 and 24 hours. Preparing 3- (4, 5-dimethylthiazole-2) -2, 5-diphenyl tetrazolium bromide (MTT, 5mg/ml) by using a serum-free culture medium according to the ratio of 1:10, adding the mixed solution into cells, and incubating for 1 hour in an incubator. Then, the supernatant was removed, and 100. mu.L of DMSO was added to dissolve the crystals sufficiently. The absorbance of each well was measured in an enzyme linked immunosorbent assay OD490 nm.
As shown in FIG. 1, the abscissa of the graph represents the action time of IL-6 at different concentrations, and the ordinate of the graph represents the OD value of absorbance, it can be seen that IL-6 at different concentrations has no significant effect on the proliferation of cells during the observation time.
2.1 detection of proteins with IL-6 activation of NF- κ B p65
Culturing HepG2 cells in a 100mm culture dish, discarding the culture medium when the cells grow to about 80%, adding the culture medium containing 30ng/mL IL-6 into the culture dish, adding the culture medium into a blank group, culturing for 0.5 h, separating cell nuclei and cell pulp by using a Biyunshi cell nucleus protein and cell pulp protein extraction kit, and detecting the expression condition of NF-kappa B p65 in the cells treated by the IL-6 in the cell nuclei and the cell pulp by using western blots.
As shown in FIG. 2-1, NF-. kappa. B p65 was normally distributed in the cytoplasm, and after IL-6 treatment, the cytoplasmic NF-. kappa. B p65 content was slightly increased, and the expression level of NF-. kappa. B p65 in the nucleus was increased.
2.2 fluorescent detection of IL-6 activation of NF- κ B p65
HepG2 cells were packed at 6X 104Passage of cultureIn 12-well plates pre-plated with sterilized slides. The next day, medium was discarded, medium at 30ng/mL IL-6 was added to the well plate, medium was added to the blank, after 0.5 hour treatment, medium was discarded, PBS washed 2 times, 4% paraformaldehyde fixed for 15 minutes, PBS washed 3 times, 5 minutes each, 0.2% Triton100 treated for 7 minutes, PBS washed 3 times, 5 minutes each, 2% BSA blocked for 1 hour, and primary antibody incubated overnight. The next day, PBS wash 3 times for 5 minutes each, FITC-labeled goat anti-rabbit IgG 1 hour, PBS wash 3 times for 5 minutes each, DAPI treatment 10 minutes, PBS wash 3 times for 5 minutes each, anti-quenching fluorescent mounting medium mounting, and imaging under a fluorescent microscope to observe the cellular localization of NF- κ B p 65.
As shown in FIG. 2-2, NF-. kappa. B p65 was normally localized to the cytoplasm, and NF-. kappa. B p65 was activated for translocation into the nucleus when HepG2 cells were treated with IL-6 at a concentration of 30 ng/mL.
The regulation of ketone body synthesis levels by NF-. kappa. B p65 is demonstrated by the activation of NF-. kappa. B p65 by IL-6.
3.1 Effect of IL-6 on beta OHB levels
HepG2 cells were cultured in 100mm dishes until the cells grew to around 80%, the medium was discarded, medium containing 30ng/mL IL-6 was added to the dishes, the blank was added with medium, and cultured for 24 hours, and the effect of IL-6 on the level of beta OHB of the cell ketone bodies was observed. At the observation point, the intracellular β OHB level was detected using an ELISA kit.
The results are shown in FIG. 3-1, with the abscissa being the concentration of IL-6 and the ordinate being the β OHB levels, from which it can be seen that 30ng/mL IL-6 was able to significantly elevate cellular β OHB levels.
3.2 modulation of Ketone anabolic enzyme HMGCS2mRNA levels by IL-6
HepG2 cells were cultured in 6-well plates, and when the cells grew to about 80%, the medium was discarded, and a medium containing 30ng/mL IL-6 was added to the well plates, and the blank group was added with the medium, cultured for 0.5 hour, and the effect of IL-6 on the cell ketone body metabolizing enzyme HMGCS2 was observed. Detecting the intracellular HMGCS2mRNA level by using a real-time quantitative PCR instrument at an observation point;
the upstream of the primer sequence of HMGCS2 is AAGTCTCTGGCTCGCCTGATGT; downstream is TCCAGGTCCTTGTTGGTGTAGG;
the upstream of the beta-actin primer sequence is TGCGTGACATTAAGGAGAAG; downstream is GCTCGTAGCTCTTCTCCA.
The results are shown in FIG. 3-2, with the concentration of IL-6 on the abscissa and the relative level of HMGCS2mRNA on the ordinate of the graph. As can be seen, 30ng/mL IL-6 was able to significantly elevate cellular HMGCS2mRNA levels.
3.3 modulation of Ketone anabolic enzyme HMGCS2 protein levels by IL-6
HepG2 cells were cultured in 6-well plates, and when the cells grew to about 80%, the medium was discarded, and a medium containing 30ng/mL IL-6 was added to the plates, and a blank group was added with the medium, and cultured for 24 hours, and the effect of IL-6 on the expression of the cellular ketone body metabolizing enzyme HMGCS2 protein was observed. At the observation point, intracellular HMGCS2 protein levels were detected using a western blot.
The results are shown in FIGS. 3-3, with the concentration of IL-6 on the abscissa and the relative level of HMGCS2 protein on the ordinate of the graph. It can be seen that 30ng/mL IL-6 was able to significantly elevate cellular HMGCS2 protein levels.
3.4 Effect of IL-6 on the Activity of the HMGCS2 promoter
Constructing pGL-HMGCS2 plasmid, firstly finding 2000bp base upstream of initiation codon of human HMGCS2 at NCBI, designing a pair of primers for amplifying the 2000bp promoter sequence, adding restriction endonuclease sites at two ends of the primers,
the upstream of the primer sequence is 5' -CGGGGTACCGAGTAGATTAAGAGTTGGGT-3’；
Downstream is 5' -CCCAAGCTTCTCCAGAGGAGCAAGCAGAA-3’；
The horizontal line parts are Kpn I and Hind III cutting sites respectively, and then the PCR products are linked to pGL3 vector by Kpn I and Hind III cutting to construct pGL3-HMGCS 2.
HepG2 cells were packed at 6X 104The cells were passaged in 6-well plates and transfected every other day, 2.55. mu.L of LX-tremageNE HP DNA transfection reagent, 1. mu.g of pGL3-HMGCS2 plasmid and 20ng of internal reference (PRL-TK) plasmid were placed in 102. mu.L of serum-free medium, gently shaken for several times, and then mixed and continued for further incubation for 30 minutes. Then adding the mixed liquid into 6-well plates respectively, placing the plates into an incubator for culture for 24 hoursAfter this time, the medium was discarded, medium containing 30ng/mL IL-6 was added to the well plate, and the blank was added with medium and incubation was continued for 24 hours. The activity of the promoter of HMGCS2 was detected using the luciferase assay kit.
As shown in FIGS. 3-4, the activity of the HMGCS2 promoter was increased by 40% in IL-6-treated HepG2 cells.
4.1 detection of HMGCS2mRNA levels by NF- κ B p65 knockout
NF-. kappa. B p65siRNA sequences were purchased from Gimeracil, where
The sense strand 5'-CCUCCUUUCAGGAGAUGAATT-3' is a strand of a sense,
the antisense strand 5'-UUCAUCUCCUGAAAGGAGGTT-3' is a strand of DNA,
the negative control siRNA sequence is sense strand 5' -UUCUCCGAACGUGUCACGUTT-3,
antisense strand 5'-ACGUGACACGUUCGGAGAATT-3'.
HepG2 cells were packed at 6X 104Transfer in 6-well plates, alternate day transfection. Respectively taking 3.5 mu LRNAimax and 7 mu L of 20 mu MsiRNA, respectively incubating in 150 mu L of serum-free culture medium for 5 minutes, uniformly mixing, gently shaking for a few times, and continuing to foster for 15-20 minutes. The mixed liquid was then added to each 6-well plate and placed in an incubator for 24 hours. Trizol is used for extracting total RNA of cells, cDNA is synthesized through reverse transcription, and PCR is quantified in real time through fluorescence to detect mRNA level change.
The results are shown in FIG. 4-1, with transfection negative control siRNA and NF-. kappa. B p65siRNA on the abscissa, and mRNA relative levels on the ordinate of the graph. As can be seen, the mRNA level of HMGCS2 was reduced by about 70% after knock-out of NF-. kappa. B p65 using NF-. kappa.BsiRNA p 65.
4.2 detection of HMGCS2 protein levels by NF- κ B p65 knockout
The transfection method is the same as 4.1, after the cells are transfected for 72 hours, extracting the total proteins of the cells, treating the cells by beta-mercaptoethanol to denature the proteins, and detecting the change of the protein levels by western blots.
The results are shown in FIG. 4-2, in which the abscissa represents transfection negative control siRNA and NF- κ B p65siRNA, and the ordinate represents protein relative level, and it can be seen from the figure that after NF- κ BsiRNA p65 knockdown NF- κ B p65, the expression of HMGCS2 is lower than that of the control group.
4.3 detection of HMGCS2 promoter Activity by NF-kappa B p65 knockout
HepG2 cells were packed at 6X 104Transfer in 6-well plates, alternate day transfection. After negative control siRNA and NF-kappa B p65siRNA were transfected for 24 hours, 2.55. mu.L of LX-tremageNE HP DNA transfection reagent, 1. mu.g of pGL3-HMGCS2 plasmid and 20ng of internal reference (PRL-TK) plasmid were placed in 102. mu.L of serum-free medium, gently shaken several times, mixed and continued for incubation for 30 minutes. The mixed liquid was then added to each 6-well plate and placed in an incubator for 48 hours. The influence on the activity of the HMGCS2 promoter after NF-kappa B p65 knockout was detected by using the luciferase assay kit.
As shown in FIGS. 4-3, the level of HMGCS2 promoter activity was reduced by about 25% in HepG2 cells after NF- κ B p65 knock-out.
5.1 prediction of potential NF-. kappa. B p65 binding site for HMGCS2 promoter
A JASPAR online analysis software is utilized to find out a conserved binding site of NF-kappa B p65, and a human HMGCS2 Gene promoter sequence (Gene ID,3158) is found in NCBI, so that a potential NF-kappa B p65 binding site of the HMGCS2 promoter is predicted.
As a result, as shown in FIG. 5-1, a conserved binding site GGAATTTCC of NF-. kappa. B p65 was found by JASPAR on-line analysis. Bioinformatics analysis of the HMGCS2 promoter shows that 6 potential binding sites of NF-kappa B p65 are contained in the HMGCS2 promoter-2000-0 region. Respectively named E-box1(GGAAGACCT), E-box2(GGAAAATCA),
E-box3(GGGAAAATG)、E-box4(AGAGTTTCC)、
E-box5(GGAACACCC)、E-box6(GGAACATCA)。
5.2 detection of potential binding sites for NF-kappa B p65 with the HMGCS2 promoter
Based on the 6 potential binding sites predicted by the software, 6 pairs of primers containing 6 potential sites were designed, and the primer sequences were as follows:
PM 1: the upstream, ATTTAAAGATAAGATCATAGACCTAGATATCCT,
downstream, AGGATATCTAGGTCTATGATCTTATCTTTAAAT;
PM 2: the upstream, GGGAGACATTCATTTCATAAATCAGATGGCAGG,
downstream, CCTGCCATCTGATTTATGAAATGAATGTCTCCC;
PM 3: the upstream, AGCTGCAGGTCTTTGCATAAATGACTCCTTTAT,
downstream, ATAAAGGAGTCATTTATGCAAAGACCTGCAGCT;
PM 4: the upstream, CTACTATTAAAAGAGTCACACTTTGGTTTAGAA,
downstream, TTCTAAACCAAAGTGTGACTCTTTTAATAGTAG;
PM 5: upstream, CACAGAGAGGAGTGTCATACACCCAGTGAGAGT;
downstream, ACTCTCACTGGGTGTATGACACTCCTCTCTGTG;
PM 6: the upstream, GATGTGATACAACAACATACATCATAACCTCCT,
downstream, AGGAGGTTATGATGTATGTTGTTGTATCACATC.
Using pGL3-HMGCS2 constructed above as a template, 6 mutant vectors were amplified using Phanta Super-Fidelity DNA polymerase, and named M1(CATAGACCT), M2(CATAAATCA), M3(GCATAAATG), M4(AGAGTCACA), M5(CATACA CCC), and M6(CATACATCA), respectively.
HepG2 cells were packed at 6X 104After passage in 6-well plates, 2.55. mu.L of LX-tremeGENE HP DNA transfection reagent, 1. mu.g of pGL3-Basic/pGL3-HMGCS2/M1/M2/M3/M4/M5/M6 plasmid/and 20ng of internal reference (PRL-TK) plasmid were placed in 102. mu.L of serum-free medium, mixed up by gentle shaking for 30 minutes and continued incubation. The mixed liquid was then added to 6-well plates, respectively, and placed in an incubator for 48 hours. The change in activity of the HMGCS2 promoter after detection of a potential binding site mutation using the luciferase assay kit.
As shown in FIG. 5-2, the HMGCS2 promoter and 6 mutant promoters were transfected into HepG2 cells, respectively. The promoter activity of HMGCS2 was reduced by about 80% after mutation of the potential binding site E-box1, the promoter activity of HMGCS2 was reduced by about 20% after mutation of the potential binding sites E-box3 and E-box6, and the promoter activity of HMGCS2 was not changed after mutation of the potential binding sites E-box2, E-box4 and E-box 5. From the above results, it was preliminarily determined that E-box1 is a binding site for NF- κ B p65 and HMGCS2 promoter.
5.3 detection of NF- κ B p65 binding directly to HMGCS2 promoter site
HepG2 was inoculated into 2 10cm plates and 8mL of each culture was added. When the cells were grown to a density of about 80%, 216. mu.L of 37% formaldehyde was added to a final concentration of about 1% and incubated at 37 ℃ for 10 minutes to crosslink the DNA with the adjacent proteins. 880. mu.L of Glycine Soulotion (10X) was added and left at room temperature for 5 minutes. The culture was removed by suction and washed twice with ice-bath PBS (1 mM PMSF in PBS and added before use). The cells were then scraped and collected into 1.5ml centrifuge tubes. Centrifuge at 2000rpm for 4 min at 4 ℃ and discard the supernatant. Add 300. mu.l SDS Lysis Buffer/dish cells containing protease inhibitor (same above) and pipette-stroke several times. Cells were lysed by sonication to cut the DNA to a size of approximately 200 and 1000 bp. In this experiment, the set ultrasonic power was 40% of the maximum power, exceeded 1 second, stopped for 1 second, and the gap time was 1 minute for a total of 8 cycles. The subsequent steps are carried out according to a Biyuntian ChIP detection kit. After obtaining DNA by ChIP kit, detecting the binding strength of different E-box and HMGCS2 promoter by real-time quantitative pcr.
The primer sequences of the 6 potential binding sites are:
HMGCS2P1(-1084--1203bp):
the upstream, TGAGTTAGAACACCAACAC,
downstream, TTCATGTTCCTACAGACAG;
HMGCS2P2(-844--953bp):
the upstream, GGTAGAGGAAGATTGGTGCTG,
downstream, CTGGTCCTTCTGCTTTGCTCT;
HMGCS2P3(-696--812bp):
the upstream, CATTCTGCAACTTCCTAGC,
downstream, GGTGACAGTTTGAAGCTCA;
HMGCS2P4(-426--548bp):
the upstream, CAACACTCACTCCCAACTC,
downstream, CACTCCTCTCTGTGGTGTTAG;
HMGCS2P5(-344--451bp):
the upstream, AACAACTAACACCACAGAGAG,
downstream, TGTATCACATCCCAAGGTAAC;
HMGCS2P6(-286—368bp):
the upstream, AGGGTTACCTTGGGATGTG,
downstream, CTCTGTGGCAGCCTTGATTC.
Human GAPDH as a control primer:
the upstream, TACTAGCGGTTTTACGGGCG,
downstream, TCGAACAGGAGGAGCAGAGAGCGA.
As shown in FIGS. 5-3, the binding effect of E-box1 to HMGCS2 promoter was enhanced, the other E-boxes did not bind to HMGCS2 promoter, and E-box1 was the binding site of NF- κ B p65 to HMGCS 2.
The combination of the above shows that: the nuclear factor NF-kappa B p65 can be combined with a promoter of ketone body synthetase HMGCS2, the expression of the enzyme is regulated from the transcription level, and HMGCS2 influences the synthesis level of ketone bodies; can activate NF-kappa B p65, regulate the expression of HMGCS2 from the transcription level, and protect AD and other neurodegenerative diseases by indirectly enhancing ketone body synthesis.
Therefore, the NF-kappa B p65/HMGCS2 can be applied to the preparation of ketogenic drugs and foods, in particular to the preparation of drugs and foods for preventing and treating neurodegenerative diseases.
The embodiments given above are preferable examples for implementing the present invention, and the present invention is not limited to the above-described embodiments. Any non-essential addition and replacement made by the technical characteristics of the technical scheme of the invention by a person skilled in the art belong to the protection scope of the invention.
Claims (3)
- The use of IL-6 in the manufacture of a medicament for ketogenesis, said medicament being a medicament for activating NF- κ B p65, enhancing expression of HMGCS2 from the transcriptional level, indirectly enhancing liver cell ketone body synthesis, said IL-6 being present at a concentration of 30 ng/mL.
- 2. The use according to claim 1, wherein the IL-6 is used in the manufacture of a medicament for the prevention or treatment of neurodegenerative diseases.
- 3. The use according to claim 1 or 2, wherein the medicament is one that enhances the binding of NF- κ B p65 to the GGAAGACCT site on the HMGCS2 promoter.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610495233.2A CN105920602B (en) | 2016-06-28 | 2016-06-28 | Application of NF-κB p65/HMGCS2 regulatory pathway in the preparation of drugs for regulating ketone body synthesis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610495233.2A CN105920602B (en) | 2016-06-28 | 2016-06-28 | Application of NF-κB p65/HMGCS2 regulatory pathway in the preparation of drugs for regulating ketone body synthesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105920602A CN105920602A (en) | 2016-09-07 |
| CN105920602B true CN105920602B (en) | 2021-07-06 |
Family
ID=56828688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610495233.2A Active CN105920602B (en) | 2016-06-28 | 2016-06-28 | Application of NF-κB p65/HMGCS2 regulatory pathway in the preparation of drugs for regulating ketone body synthesis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105920602B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552760A (en) * | 2012-03-13 | 2012-07-11 | 陈淑香 | Nursing liquid for eczema |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020131954A1 (en) * | 2000-05-02 | 2002-09-19 | Tobinick Edward L. | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| EP1999146B1 (en) * | 2006-03-13 | 2012-05-30 | Liat Mintz | Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation |
-
2016
- 2016-06-28 CN CN201610495233.2A patent/CN105920602B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552760A (en) * | 2012-03-13 | 2012-07-11 | 陈淑香 | Nursing liquid for eczema |
Non-Patent Citations (1)
| Title |
|---|
| TNF-α and IL-6 Synergistically Inhibit Ketogenesis From Fatty Acids and α-Ketoisocaproate in Isolated Rat Hepatocytes;Karine Pailla，等;《Journal of Parenteral and Enteral Nutrition》;19981031;第22卷(第5期);摘要和第288-289页结果、讨论部分 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105920602A (en) | 2016-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | LncRNA GAS5 regulates ischemic stroke as a competing endogenous RNA for miR-137 to regulate the Notch1 signaling pathway | |
| Han et al. | Serum deprivation results in redifferentiation of human umbilical vascular smooth muscle cells | |
| Elia et al. | The knockout of miR-143 and-145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease | |
| Mammucari et al. | FoxO3 controls autophagy in skeletal muscle in vivo | |
| Chu-Tan et al. | MicroRNA-124 dysregulation is associated with retinal inflammation and photoreceptor death in the degenerating retina | |
| Kook et al. | Involvement of JNK-AP-1 and ERK-NF-κB signaling in tension-stimulated expression of type I collagen and MMP-1 in human periodontal ligament fibroblasts | |
| Croce et al. | NPY modulates miR-30a-5p and BDNF in opposite direction in an in vitro model of Alzheimer disease: a possible role in neuroprotection? | |
| Chen et al. | Mir30c is involved in diabetic cardiomyopathy through regulation of cardiac autophagy via BECN1 | |
| Hu et al. | Src promotes anti-inflammatory (M2) macrophage generation via the IL-4/STAT6 pathway | |
| Wang et al. | Apigenin attenuates TGF-β1-stimulated cardiac fibroblast differentiation and extracellular matrix production by targeting miR-155-5p/c-Ski/Smad pathway | |
| Zhang et al. | MiR-195 dependent roles of mitofusin2 in the mitochondrial dysfunction of hippocampal neurons in SAMP8 mice | |
| Iwata et al. | Transforming Growth Factor-β Regulates Basal Transcriptional Regulatory Machinery to Control Cell Proliferation and Differentiation in Cranial Neural Crest-derived Osteoprogenitor Cells 2 | |
| Liu et al. | Pioglitazone up-regulates long non-coding RNA MEG3 to protect endothelial progenitor cells via increasing HDAC7 expression in metabolic syndrome | |
| Sun et al. | MiR-298 exacerbates ischemia/reperfusion injury following ischemic stroke by targeting Act1 | |
| Wang et al. | miR‐154‐5p functions as an important regulator of angiotensin II‐mediated heart remodeling | |
| Zeng et al. | Diverging targets mediate the pathological role of miR-199a-5p and miR-199a-3p by promoting cardiac hypertrophy and fibrosis | |
| Wen et al. | Preserving mitochondrial function by inhibiting GRP75 ameliorates neuron injury under ischemic stroke | |
| Liu et al. | Down-regulation of Wnt10a affects odontogenesis and proliferation in mesenchymal cells | |
| Phạm et al. | miRNA 146a-5p-loaded poly (d, l-lactic-co-glycolic acid) nanoparticles impair pain behaviors by inhibiting multiple inflammatory pathways in microglia | |
| Chu et al. | Function of Krüppel-like factor 2 in the shear stress-induced cell differentiation of endothelial progenitor cells to endothelial cells | |
| Sugiyama et al. | ERAD components Derlin-1 and Derlin-2 are essential for postnatal brain development and motor function | |
| Guan et al. | Progranulin administration attenuates β-amyloid deposition in the Hippocampus of 5xFAD mice through modulating BACE1 expression and microglial phagocytosis | |
| Zong et al. | Possible role of Pax-6 in promoting breast cancer cell proliferation and tumorigenesis | |
| Hu et al. | LncRNA 1700020I14Rik/miR-297a/CGRP axis suppresses myocardial cell apoptosis in myocardial ischemia-reperfusion injury | |
| Li et al. | Long non-coding RNA MEG3 promotes tumor necrosis factor-alpha induced oxidative stress and apoptosis in interstitial cells of cajal via targeting the microRNA-21/I-kappa-B-kinase beta axis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |